Thermo Fisher Scientific has announced plans to invest $130 million for a new sterile manufacturing facility in Singapore.

The new facility will initially include a high-speed sterile line approved for live virus filling and an additional line for standard fill–finish. The facility will also have cleanroom capacity, labs, warehousing, and offices to support production. Once operational in 2022, the facility could manufacture up to 30 million sterile doses per month and employ more than 300 people.

The facility is being established with the support of the Singapore Economic Development Board and will be operated by Thermo Fisher and will have the capability to manufacture pharmaceutical products to meet regional demand.

In a separate development, the company announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell-therapy processing system.

Source: Thermo Fisher (sterile manufacturing) and Thermo Fisher (cell-therapy processing system)